AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11732460
Drug: Separate administrations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administrations of DTP‐HBV and Hib vaccines
Trial: 3134739
Drug: Magnyl (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnyl (plain acetylsalicylic acid) 75 mg daily for 2 weeks
Trial: 3134739
Drug: Globentyl (micro-encapsulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Globentyl (micro-encapsulated acetylsalicylic acid) 75 mg daily for 2 weeks
Trial: 27148676
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg by mouth once daily, with a possible increase to 200 mg depending on response)
Trial: 23277434
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between EVLW-T and EVLW-G
Trial: 9915315
Drug: Milrinone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (30 microg/kg bolus administered progressively in 10 min, followed by a continuous infusion of 0.5 microg x kg(‐1) x min(‐1))
Trial: 7675954
Drug: 8.33 mg
RxNorm normalized name: ombitasvir 8.33 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.33 mg phenylpropanolamine gum
Trial: 1665178
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg and Hydrochlorothiazide 12.5 mg once daily (L/HCTZ)
Trial: 1665178
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg and Hydrochlorothiazide 25 mg once daily (C/HCTZ)
Trial: 7235321
Drug: Metaproterenol metered
RxNorm normalized name: metaproterenol Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol metered dose aerosol (1.5 mg)
Trial: 25056444
Drug: Placebo expectation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo expectation group (told the cream would reduce pain)
Trial: 25056444
Drug: No-expectation group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-expectation group (told the cream was a hand cleanser)
Trial: 23436265
Drug: etravirine 200
RxNorm normalized name: etravirine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etravirine 200 mg bid for 8 days
Trial: 23436265
Drug: lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir 400/100 mg bid for 16 days with etravirine 200 mg bid on days 9-16
Trial: 21045816
Drug: EST followed
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EST followed by mechanical lithotripsy (ML)
Trial: 9084513
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion of propofol (10‐12 mg/kg/h) and alfentanil (25 micrograms/kg/h) for 2 min, followed by atracurium (5 mg) and propofol (1‐1.5 mg/kg) as a bolus induction dose over 20 s.
Trial: 9084513
Drug: Thiamylal (4‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal (4‐5 mg/kg) and fentanyl (2 micrograms/kg), atracurium (5 mg) and succinylcholine (1.5 mg/kg).
Trial: 9084513
Drug: Thiamylal (4‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal (4‐5 mg/kg) with additional sublingual nifedipine (1/2 capsule) 10 min prior to induction.
Trial: 1879184
Drug: Intramuscular imipenem/cilastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular imipenem/cilastatin (500 or 750 mg every 12 hours)
Trial: 1879184
Drug: Intramuscular imipenem/cilastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular imipenem/cilastatin
Trial: 1879184
Drug: Intramuscular imipenem/cilastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular imipenem/cilastatin (500 mg)
Trial: 24300843
Drug: Half-dose sinogram-affirmed
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose sinogram-affirmed iterative reconstruction (HD-SAFIRE(2))
Trial: 24300843
Drug: Full-dose filtered
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose filtered back projection images (FD-FBP)
Trial: 19139424
Drug: Cisplatin-based concurrent
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based concurrent chemoradiotherapy
Trial: 19139424
Drug: Mitomycin-based therapy
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-based therapy
Trial: 15528874
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with losartan and trandolapril
Trial: 2694142
Drug: Chlortenoxicam 4
RxNorm normalized name: Chlortenoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortenoxicam 4 mg
Trial: 411434
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin infusion at the rate of 6 units per hour
Trial: 411434
Drug: High-dose, intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose, intermittent subcutaneously administered insulin
Trial: 26474517
Drug: Cediranib 20
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib 20 mg orally once daily until disease progression
Trial: 23815798
Drug: Prothrombin complex
RxNorm normalized name: prothrombin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrate administration prior to surgery
Trial: 23815798
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration prior to surgery
Trial: 15285023
Drug: DA-9601 180
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-9601 180 mg
Trial: 15285023
Drug: DA-9601 360
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-9601 360 mg
Trial: 15285023
Drug: Cetraxate 600
RxNorm normalized name: Cetraxal
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetraxate 600 mg
Trial: 9269642
Drug: RenaGel 1
RxNorm normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RenaGel 1 g
Trial: 9269642
Drug: RenaGel 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RenaGel 2.5 g
Trial: 9269642
Drug: RenaGel 5
RxNorm normalized name: RenaGel
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RenaGel 5 g
Trial: 1586329
Drug: Intravenous Syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Syntocinon
Trial: 3308584
Drug: Exogenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exogenous insulin
Trial: 18373318
Drug: MCP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP treatment for 30 minutes during eight days
Trial: 18373318
Drug: No MCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No MCP treatment
Trial: 8655293
Drug: Pentoxifylline at
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline at a dose of 800 mg thrice daily
Trial: 435053
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no albumin therapy)
Trial: 6312460
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefotiam twice daily for 10 days
Trial: 6312460
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cephalothin 4-times daily for 10 days
Trial: 30778742
Drug: Receiving chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving chemotherapy
Trial: 26475499
Drug: 0.12 %
RxNorm normalized name: Oris 0.12 % Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 % CHX + 0.05 % CPC (Perio-Aid® Treatment alcohol-free)
Trial: 26475499
Drug: 0.03 %
RxNorm normalized name: menthol 0.03 % Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 % CHX + 0.05 % CPC new test formulation
Trial: 11872656
Drug: Increased plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased plasma amino acids (approximately 4.6 mmol/l)
Trial: 523673
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) administered via tablets, gel, and pessary bases
Trial: 27681813
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of hyaluronic acid 1.6% (group A)
Trial: 27681813
Drug: Syalox 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syalox 300 Plus® (hyaluronic acid 300 mg + Boswellia serrata extract 100 mg) for 20 days followed by Syalox 150® (hyaluronic acid 150 mg) for another 20 days (group B)
Trial: 19438847
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (250-1000 mg/bid i.v.) plus hypertonic saline solutions (150 mL H(2)O with NaCl 1.4-4.6%)
Trial: 19438847
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide plus hypertonic saline solutions
Trial: 19438847
Drug: Repeated paracentesis
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated paracentesis and standard diuretic schedule
Trial: 8346832
Drug: Nitroprusside and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside and diltiazem (bolus of 80 micrograms/kg with two consecutive infusions of 4.5 micrograms.kg‐1.min‐1 during the first 30 min and then 1.3 micrograms.kg‐1.min‐1)
Trial: 3567466
Drug: CT with
RxNorm normalized name: Impact with Fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT with 16.25 g iodine contrast medium
Trial: 3567466
Drug: CT with
RxNorm normalized name: Impact with Fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT with 32.5 g iodine contrast medium
Trial: 3567466
Drug: CT without
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT without intravenous contrast medium
Trial: 29798249
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled intravenous analgesia (Group A)
Trial: 29798249
Drug: Ibuprofen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (5 mg/kg/sub) (Group B)
Trial: 21908460
Drug: Abrupt quitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrupt quitting with nicotine lozenge, quit date set between 1 and 3 weeks after study onset.
Trial: 21908460
Drug: Gradual quitting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual quitting with nicotine lozenge, quit date set between 3 and 5 weeks after study entry.
Trial: 16488057
Drug: 2‐L pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐L pulse lavage normal saline washout
Trial: 16488057
Drug: 2‐L normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐L normal saline washout via a jug or a syringe
Trial: 8856712
Drug: Adenosine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (low dose)
Trial: 8856712
Drug: Adenosine (increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (increasing doses)
Trial: 6094373
Drug: NaHCO3 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (0.2 g/kg B.W.)
Trial: 27049826
Drug: Hydromorphone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (up to 3 times daily for 6 months)
Trial: 27049826
Drug: Diacetylmorphine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacetylmorphine (up to 3 times daily for 6 months)
Trial: 25057155
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe with water
Trial: 25057155
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe with food
Trial: 25057155
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg Fe with food
Trial: 25057155
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe without food
Trial: 22192729
Drug: Intravenous aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous aflibercept (4 mg/kg every 2 weeks)
Trial: 24127346
Drug: Intravenous aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous aflibercept
Trial: 17097649
Drug: Intramuscular methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular methotrexate 50 mg/m(2) administered on days 0 and 4; additional doses on day 7 and/or day 11 if hCG levels did not decrease by 15%
Trial: 16199417
Drug: Single-injection thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection thoracic paravertebral block with bupivacaine 0.375% and adrenaline 1:200 000 0.4 ml kg(‐1) plus i.v. patient‐controlled analgesia (PCA) with morphine
Trial: 16199417
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with back puncture without injection and morphine PCA
Trial: 7478700
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral tramadol
Trial: 7478700
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg paracetamol + 60 mg codeine (active control)
Trial: 1545135
Drug: Sphingosines (D-sphingosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sphingosines (D-sphingosine, D,L-sphinganine, 4-D-hydroxysphinganine, oleoyl-sphingosine, N,N-dimethylsphingosine)
Trial: 29119559
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous methylprednisolone (MP) 125 mg
Trial: 23828016
Drug: Ultrasound-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intra-articular injection
Trial: 23828016
Drug: Palpation-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided intra-articular injection
Trial: 20489027
Drug: lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir 400/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Trial: 20489027
Drug: darunavir/ritonavir 600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 600/100 mg twice daily coadministered with S/GSK1349572 30 mg once daily for 14 days
Trial: 20489027
Drug: S/GSK1349572 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/GSK1349572 30 mg once daily
Trial: 15095653
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment of all cardiovascular risk factors
Trial: 11342895
Drug: Oxybutynin 2.5
RxNorm normalized name: oxyBUTYnin 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 2.5 mg twice daily (increased to 5 mg after 2 weeks)
Trial: 1539476
Drug: Propofol anaesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anaesthesia (Group G)
Trial: 1539476
Drug: p-deletion score
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-deletion score (Group G)
Trial: 3886311
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with penicillin/pivampicillin
Trial: 30995174
Drug: Pelvic Radiation
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic Radiation Therapy (RT) at 45 to 50.4 Gy over 5 weeks
Trial: 26045170
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg • kg(-1) anhydrous caffeine)
Trial: 25440232
Drug: Bone injection
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone injection gun (BIG)
Trial: 10075337
Drug: Oral biotin
RxNorm normalized name: biotin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral biotin (2.1 micromol)
Trial: 10075337
Drug: Oral biotin
RxNorm normalized name: biotin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral biotin (8.2 micromol)
Trial: 10075337
Drug: Oral biotin
RxNorm normalized name: biotin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral biotin (81.9 micromol)
Trial: 10075337
Drug: Intravenous biotin
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous biotin (18.4 micromol)
Trial: 10075337
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of biotin (oral and intravenous)
Trial: 10075337
Drug: Intravenous biotin
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous biotin and largest oral dose
Trial: 434682
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug regimen (beta-lactam antibiotic)
Trial: 434682
Drug: Combination antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antibiotic regimen (beta-lactam antibiotic + aminoglycoside)
Trial: 21857273
Drug: Single-injection sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection sciatic nerve block (Fs group)
Trial: 18718986
Drug: Etanercept added
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept added to methotrexate monotherapy
Trial: 18718986
Drug: Methotrexate added
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate added to etanercept monotherapy
Trial: 18718986
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (etanercept + methotrexate)
Trial: 28196046
Drug: Test (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test (new oral formulation of levosulpiride, tablet 25 mg)
Trial: 28196046
Drug: Reference (commercially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference (commercially available formulation, tablet 25 mg)
Trial: 25355797
Drug: Nonadjuvanted whole‐virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine (doses ranging from 3.75 to 45 μg of hemagglutinin antigen)
Trial: 25355797
Drug: Nonadjuvanted whole‐virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted whole‐virus G9 lineage H9N2 influenza virus vaccine
Trial: 24292351
Drug: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOO (1(3)‐behenoyl‐2,3(1)‐dioleoyl‐rac‐glycerol) intake of 2.46 g/day for 7 days
Trial: 10480191
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg of cerivastatin sodium once daily
Trial: 10480191
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg of cerivastatin sodium once daily
Trial: 10480191
Drug: Combined results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined results of 0.3 mg and 0.15 mg groups
Trial: 8620266
Drug: Computer-assisted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted treatment planner
Trial: 8620266
Drug: Interactive patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive patient education/therapy
Trial: 26520401
Drug: Parenteral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily (ARTES)
Trial: 26520401
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of quinine base at 16.6 mg/kg followed by maintenance dose of 8.3 mg/kg (QLD)
Trial: 26520401
Drug: 8.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.3 mg/kg quinine base every 8 hours (QNLD3)
Trial: 26520401
Drug: 12.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/kg quinine base every 12 hours (QNLD2)
Trial: 22021142
Drug: PHILOS augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHILOS augmentation plus minimally invasive injectable graft (MIIG) X3 Hivisc (Group B)
Trial: 18723296
Drug: Concurrent cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin-based chemotherapy (Group 3)
Trial: 18723296
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and concurrent chemotherapy
Trial: 18723296
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose to the cochlea